Rhinovirus-A16
PreclinicalBiologic
Rhinovirus-A16 is one of 39 biologic programs targeting Chronic Obstructive Pulmonary Disease. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
38
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
119 competitors in Chronic Obstructive Pulmonary Disease
#DrugCompanyPhaseTrials
1Lunsekimig
SanofiPhase 3
CM310
KKeymed Biosciences Co.Ltd
Phase 3
Sildenafil ODT
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 2
Tozorakimab
AstraZenecaPhase 3
Astegolimab
RochePhase 3
CM512
KKeymed Biosciences Co.Ltd
Phase 2
HSK39004
Haisco Pharmaceutical Group Co., Ltd.Phase 2
RLS-0071
RReAlta Life Sciences, Inc.
Phase 2
Calciferol
Jazz PharmaceuticalsPreclinical
Duragesic
CCephalon
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Rhinovirus-A16. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Preclinical[1]
- Company
- IImperial College London